Showing 1 - 5 results of 5 for search 'Karl D Lewis', query time: 0.05s Refine Results
  1. 1
    Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

    Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a... by Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno

    Published 2020-08-01
    Get full text
    Article
  2. 2
    IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients

    IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients by Richard P. Tobin, Kimberly R. Jordan, Puja Kapoor, Eric Spongberg, Dana Davis, Victoria M. Vorwald, Kasey L. Couts, Dexiang Gao, Derek E. Smith, Jessica S. W. Borgers, Jessica S. W. Borgers, Steven Robinson, Carol Amato, Rene Gonzalez, Rene Gonzalez, Karl D. Lewis, Karl D. Lewis, William A. Robinson, William A. Robinson, Virginia F. Borges, Virginia F. Borges, Virginia F. Borges, Martin D. McCarter, Martin D. McCarter

    Published 2019-11-01
    Get full text
    Article
  3. 3
    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial by Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem

    Published 2018-01-01
    Get full text
    Article
  4. 4
    Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

    Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy by Carol M. Amato, Jennifer D. Hintzsche, Keith Wells, Allison Applegate, Nicholas T. Gorden, Victoria M. Vorwald, Richard P. Tobin, Kelsey Nassar, Yiqun G. Shellman, Jihye Kim, Theresa M. Medina, Matthew Rioth, Karl D. Lewis, Martin D. McCarter, Rene Gonzalez, Aik-Choon Tan, William A. Robinson

    Published 2020-07-01
    Get full text
    Article
  5. 5
    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... by Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Karl D Lewis, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur

    Published 2022-12-01
    Get full text
    Article

Search Tools: